HIGHLIGHTS
- who: Pier Vitale Nuzzo from the (UNIVERSITY) have published the Article: Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer, in the Journal: (JOURNAL)
- what: The authors aimed to evaluate a prognostic model based on the time of disease presentation (after prior local therapy or de-novo ) and disease burden (low volume or high-volume ) at AA/Enza onset for mCRPC patients receiving either AA or Enza as first-line. The Creative Commons . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.